US7129232 — Cephem compounds
Method of Use · Assigned to Wakunaga Pharmaceutical Co Ltd · Expires 2028-05-15 · 2y remaining
What this patent protects
This patent protects a compound of the formula [I] and its pharmaceutically acceptable salts, as described in the abstract.
USPTO Abstract
The present invention relates to a compound of the formula [I]: wherein R<SUP>1 </SUP>is lower alkyl, hydroxy(lower)alkyl or halo(lower)alkyl, and R<SUP>2 </SUP>is hydrogen or amino protecting group, or R<SUP>1 </SUP>and R<SUP>2 </SUP>are bonded together and form lower alkylene or lower alkenylene; R<SUP>3 </SUP>is hydrogen or lower alkyl; R<SUP>4 </SUP>is R<SUP>5 </SUP>is carboxy or protected carboxy; and R<SUP>6 </SUP>is amino or protected amino, or a pharmaceutically acceptable salt thereof, a process for preparing a compound of the formula [I], and a pharmaceutical composition comprising a compound of the formula [I] in admixture with a pharmaceutically acceptable carrier.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-36 |
— |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.